Lytgobi® (futibatinib)
for Cholangiocarcinoma – Bile Duct Cancer
Lytgobi (futibatinib) is a kinase inhibitor used to treat adults with bile duct cancer (cholangiocarcinoma) that is metastatic or cannot be removed by surgery. It is prescribed for patients who have already received prior treatment and whose tumors have an abnormal FGFR2 gene. Lytgobi works by blocking the abnormal protein that signals cancer cells to multiply, helping to slow or stop cancer growth.
